MultiCell Technologies, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc.

MCET 0.000001000

-90.0%

Jun 6 1:41 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jimpit who wrote (184)	10/24/2006 9:22:01 PM
From: jimpit	of 237

More... d. for j. ____________________________________________________________ MULTICELL TECHNOLOGIES, INC. Files SEC form 10QSB, Quarterly Report EDGAR Online (Tue, Oct 17) biz.yahoo.com MultiCell CEO to Discuss First-in-Class Drug Candidates and IP Expansion in Online Interview with MN1.com Investment Broadcaster A CEO to Highlight Proprietary Immune-Modulation Technology to Create Breakthrough Treatments for MS, Influenza, Diabetes and Other Conditions Tuesday Oct 24 2006 06:30:25 EDT SAN DIEGO, Oct 24, 2006 (BUSINESS WIRE) -- new.quote.com MultiCell Establishes Clinical Development Team to Lead UK Phase IIb Human Clinical Trials for MCT-125 for the Treatment of Fatigue in MS Patients Business Wire (Tue., Oct. 24, 2006 4:04pm) biz.yahoo.com ______________________________________________________________

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next